Oxford BioMedica (CHIX:OXBL) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:OXBL Oxford BioMedica PLC CHIX:OXBL
71 GF Score
Price £6.51
GF Value £5.40
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica FFO per Share?

FFO per Share only applies to REITs.

CHIX:OXBL
71GF Score
Oxford BioMedica PLC CHIX:OXBL
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oxford BioMedica (CHIX:OXBL) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of £6.51 is trading 20.6% above its estimated GF Value™ of £5.40. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for CHIX:OXBL:

  • FFO per Share:
  • GF Value™: £5.40 vs. price of £6.51 (20.6% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the CHIX:OXBL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBDF:USAOXB:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score

Get the complete analysis for CHIX:OXBL

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£6.51
Price
£5.40
GF Value